Skip to content

68Ga-PSMA PET/CT Imaging in Assessment of Prostate Cancer

68Ga-PSMA PET/CT Imaging in Assessment of PCa: Feasibility of Delayed Acquisition on Total-body PET/CT Scanner?

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05134064
Enrollment
66
Registered
2021-11-24
Start date
2020-12-01
Completion date
2021-08-31
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IMAGE, PET/CT, Prostate Specific Membrane Antigen

Brief summary

Dual-time point 68Ga-PSMA PET/CT could increase the lesion detection in PCa patients, it remains difficult to perform in clinical practice. The possibility of one-time point 68Ga-PSMA PET/CT imaging could be achieved using a total-body PET/CT.

Interventions

DEVICEtotal-body PET/CT

PCa patients who underwent PSMA PET/CT in our clinical center received two-time points scans at 1 h p.i. and 3 h p.i. on a total-body PET/CT scanner.

Sponsors

RenJi Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

* primary staging of pathology-confirmed PCa or evidence of BCR with PSA value \> 0.2 ng/ml * positive 68Ga-PSMA findings * both standard and delayed scans were performed on the total-body PET/CT

Exclusion criteria

* only one scan was performed * negative PSMA results

Design outcomes

Primary

MeasureTime frameDescription
Only one-time point scan is possible for PSMA PET/CT8 monthsBy the use of total- body PET/CT scanner, the imaging quality between the 1 h p.i. and 3 h p.i. imaging acquisition are compared. And the different lesion detection rates at 3 h p.i. and 1 h p.i. are also discussed. The uptake value differences of all lesions are compared.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026